Innocan has reported a new clinical success in its Compassionate Care Trial, which focuses on treating dogs with cannabidiol (CBD).

Innocan, a Canadian pharmaceutical technology company, says participating canines have experienced improved walking abilities and significant pain reduction.

The clinical trial is one of Innocan’s cannabinoid science-based approaches to improving patients’ quality of life.

One of the dogs Innocan treated was Lady, an 11-year-old dachshund mixed breed with severe autoimmune mediated polyarthritis.

The company says Lady’s condition left her in severe pain and unable to walk.

Before the trial, Lady had received joint supplements (Glycoflex), steroids, and hydrotherapy treatments with little success.

According to the company, the dog was still very lame and could not walk more than a few steps.

But Innocan says Lady began improving after joining the clinical trial.

“We couldn’t be more thrilled than to be able to assist a poor creature in pain,” says Innocan CEO Iris Bincovich. “2023 started with rapid clinical and IP performance, igniting the hope that we are getting closer to advanced availability of treatments. We believe that our ability to help Lady will also contribute to our ability to bring CBD-based pharma solutions to the market.”

The company says its liposomal CBD delivery platform facilitates precise dosing and controlled release into the bloodstream over time.

Currently, the platform is in the preclinical trial phase for epilepsy and pain.

Innocan administered its liposomal CBD injections to Lady in addition to her other treatments in December 2022.

The company says Lady began demonstrating noticeable improvements, walking farther distances faster than before.

Innocan says Lady’s improved condition lasted more than five weeks following treatments, indicating that the liposomal CBD formulation is long-lasting.

In addition to the liposomal CBD platform, Innocan is also studying the medicinal properties of its CBD-loaded exosomes platform (CLX).

The company says the CLX platform could have potential regenerative and anti-inflammatory benefits for the central nervous system.

By Benjie Cooper

Raised on geek culture, Benjie has been in cannabis news since 2014, and a consumer since long before that. Before starting CannaGeek, he wrote for the Candid Chronicle and co-hosted the Nug Life Radio Show.

Leave a Reply

Your email address will not be published. Required fields are marked *